{"id":4718,"date":"2019-04-10T16:50:20","date_gmt":"2019-04-10T11:20:20","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4718"},"modified":"2025-05-08T11:50:23","modified_gmt":"2025-05-08T06:20:23","slug":"gene-therapy-in-oncology","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-in-oncology","title":{"rendered":"The promising Pipeline for Gene Therapy In Oncology"},"content":{"rendered":"\n<p class=\"has-drop-cap\"><strong>Gene therapy<\/strong> is a technique that involves replacing, inactivating, or adding a new gene to treat or prevent a disease. The science of GENE THERAPY involves the DNA-based changes in genetic material so that the gene can transcribe a healthy protein. In the past, there has been no success in designing any gene therapies to treat any disease effectively. But recent years saw a boost in the advancements in this area. \u00a0Recent clinical breakthroughs in the field of Gene therapy have given a new ray of hope to the patients suffering from <strong>cancer<\/strong>, <strong>retinal<\/strong> <strong>disease, <a href=\"https:\/\/www.delveinsight.com\/report-store\/hemophilia-b-pipeline-insight\">haemophilia<\/a>, neurodegenerative conditions<\/strong>, and other diseases. The <strong>U.S. Food and Drug Administration<\/strong> (<strong>FDA<\/strong>), over past years, has approved many gene therapy products to treat types of cancer and overcome vision loss. \u00a0<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><strong>GENE THERAPY IN ONCOLOGY <\/strong><\/h4>\n\n\n\n<p>In<strong> Oncology<\/strong>, there exists only three marketed Gene Therapy products <strong>Oncorine<\/strong> (marketed in 2006), <strong>Provenge<\/strong> (2010) and <strong>Imlygic<\/strong> (marketed in 2015) which have been manufactured so far. <strong><g class=\"gr_ gr_7 gr-alert gr_spell gr_inline_cards gr_disable_anim_appear ContextualSpelling ins-del multiReplace\" id=\"7\" data-gr-id=\"7\">Kymriah<\/g><\/strong> and <strong>Yescarta, <\/strong>are the two other therapies approved by the<strong> FDA <\/strong>to fight cancer termed as <strong>CAR-T therapy<\/strong>. <strong><g class=\"gr_ gr_9 gr-alert gr_spell gr_inline_cards gr_disable_anim_appear ContextualSpelling ins-del multiReplace\" id=\"9\" data-gr-id=\"9\">Kymriah<\/g><\/strong> treats a bone marrow cancer and <strong>Yescarta<\/strong>-a type of lymphoma. Numerous targets or genes, such as CD4 + \/ CD8 + cells (Axalimogene <g class=\"gr_ gr_10 gr-alert gr_spell gr_inline_cards gr_disable_anim_appear ContextualSpelling\" id=\"10\" data-gr-id=\"10\">filolisbac<\/g>), thymidine kinase (Pexa-Vec) are under research that might hold the potential to targets cancer when redesigned using Gene therapy.<br><strong>Provenge<\/strong> (sipuleucel-T) is the first, and the only <strong>FDA approved<\/strong>, personalised (an autologous) cellular immunotherapy, indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-prostate-cancer-market\">prostate cancer<\/a><\/strong>.This <strong>\u2018somatic cell therapy product\u2019 <\/strong>marketed by Dendron Corporation, in 2017 acquired by <strong><g class=\"gr_ gr_18 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling ins-del multiReplace\" id=\"18\" data-gr-id=\"18\">SanPower<\/g><\/strong>.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s analysis, the pipeline of gene therapy in cancer appears to be very strong with a total of 47 products in development. Out of these, around 11% products are in Phase III, 43% are in Phase II, 11% are in Phase I, and 17% of the therapies are given IND (Investigational New Drug) status, and around 19% of the gene therapies are still in pre-clinical and discovery stages. <strong><g class=\"gr_ gr_7 gr-alert gr_spell gr_inline_cards gr_run_anim ContextualSpelling ins-del multiReplace\" id=\"7\" data-gr-id=\"7\">Advantagene<\/g><\/strong> and <strong>Advaxis<\/strong> are the two companies that are leading with their products in the phase III development phase. The highest number of Gene therapy clinical products for cancer is with <strong>Takara Bio<\/strong> (three products), and the largest number of non-clinical products is with <strong>CZ Biomed<\/strong> (eight products). Advaxis (also known asADXS11-001 (Attenuated Live Listeria Encoding HPV 16 E7 Vaccine) is in various stages of development for the treatment of High-risk locally advanced<a href=\"https:\/\/www.delveinsight.com\/report-store\/cervical-cancer-market\"> <strong>Cervical Cancer<\/strong>,<\/a> Persistent or Recurrent Metastatic (Squamous or Non-Squamous Cell) <a href=\"https:\/\/www.delveinsight.com\/report-store\/cutaneous-squamous-cell-carcinoma-cscc-epidemiology-forecast\"><strong>Carcinoma<\/strong> <\/a>and HPV-associated locally Advanced <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/anal-cancer-market\">Anal Cancer<\/a>.<\/strong><\/p>\n\n\n\n<p>Gene therapy had its ups and downs, but it sailed through all the tough times. Scientists believe <strong>Gene therapy<\/strong> to be a one-shot solution. Because it does not treat just the symptoms but eliminates the disease from the roots. With the rise in acceptance of Gene Therapy as a treatment tool, it sure holds a promising future. Although with the challenges and risk associated, it remains a risky domain. <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Gene therapy is a technique that involves replacing, inactivating, or adding a new gene to treat or prevent a disease. The science of GENE THERAPY involves the DNA-based changes in genetic material so that the gene can transcribe a healthy protein. In the past, there has been no success in designing any gene therapies to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":4723,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[137,2853,2851,17696,258,259,3154,427,428,593],"industry":[17225],"therapeutic_areas":[17235,17228],"class_list":["post-4718","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-cancer","tag-cd4-t","tag-cd8-t-cells","tag-cell-and-gene-therapy","tag-gene-therapy","tag-gene-therapy-pipeline-assessment","tag-haemophilia","tag-oncology","tag-oncology-reports","tag-us-food-and-drug-administration-fda","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>The promising Pipeline for Gene Therapy In Oncology | DelveInsight<\/title>\n<meta name=\"description\" content=\"The science of GENE THERAPY involves the DNA-based changes in genetic material so that the gene can transcribe a healthy protein... and treat cancer...\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-in-oncology\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The promising Pipeline for Gene Therapy In Oncology | DelveInsight\" \/>\n<meta property=\"og:description\" content=\"The science of GENE THERAPY involves the DNA-based changes in genetic material so that the gene can transcribe a healthy protein... and treat cancer...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/gene-therapy-in-oncology\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-04-10T11:20:20+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-08T06:20:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021400\/Untitled-Project.png\" \/>\n\t<meta property=\"og:image:width\" content=\"2312\" \/>\n\t<meta property=\"og:image:height\" content=\"1156\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"The promising Pipeline for Gene Therapy In Oncology | DelveInsight","description":"The science of GENE THERAPY involves the DNA-based changes in genetic material so that the gene can transcribe a healthy protein... and treat cancer...","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-in-oncology","og_locale":"en_US","og_type":"article","og_title":"The promising Pipeline for Gene Therapy In Oncology | DelveInsight","og_description":"The science of GENE THERAPY involves the DNA-based changes in genetic material so that the gene can transcribe a healthy protein... and treat cancer...","og_url":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-in-oncology","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-04-10T11:20:20+00:00","article_modified_time":"2025-05-08T06:20:23+00:00","og_image":[{"width":2312,"height":1156,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021400\/Untitled-Project.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-in-oncology","url":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-in-oncology","name":"The promising Pipeline for Gene Therapy In Oncology | DelveInsight","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-in-oncology#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-in-oncology#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021400\/Untitled-Project.png","datePublished":"2019-04-10T11:20:20+00:00","dateModified":"2025-05-08T06:20:23+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"The science of GENE THERAPY involves the DNA-based changes in genetic material so that the gene can transcribe a healthy protein... and treat cancer...","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/gene-therapy-in-oncology"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/gene-therapy-in-oncology#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021400\/Untitled-Project.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021400\/Untitled-Project.png","width":2312,"height":1156,"caption":"Gene Therapy in Oncology"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/04\/09021400\/Untitled-Project-300x150.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">CD4 T<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">CD8 T cells<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cell and Gene Therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Gene Therapy Pipeline Assessment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Haemophilia<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Oncology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Oncology reports<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">US Food and Drug Administration (FDA)<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">CD4 T<\/span>","<span class=\"advgb-post-tax-term\">CD8 T cells<\/span>","<span class=\"advgb-post-tax-term\">Cell and Gene Therapy<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">Gene Therapy Pipeline Assessment<\/span>","<span class=\"advgb-post-tax-term\">Haemophilia<\/span>","<span class=\"advgb-post-tax-term\">Oncology<\/span>","<span class=\"advgb-post-tax-term\">Oncology reports<\/span>","<span class=\"advgb-post-tax-term\">US Food and Drug Administration (FDA)<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 12 months ago"},"absolute_dates":{"created":"Posted on Apr 10, 2019","modified":"Updated on May 8, 2025"},"absolute_dates_time":{"created":"Posted on Apr 10, 2019 4:50 pm","modified":"Updated on May 8, 2025 11:50 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4718","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4718"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4718\/revisions"}],"predecessor-version":[{"id":31879,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4718\/revisions\/31879"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4723"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4718"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4718"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4718"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4718"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4718"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}